Protalix BioTherapeutics (PLX) FCF Margin Growth (3y) (2013 - 2026)
Protalix BioTherapeutics (PLX) FCF Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -1,272.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -2,228.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5,426.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9,545.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4,612.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1,850.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 14,060.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -3,088.00 |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | -6,907.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6,907.00 |
| Mar 31, 2026 | 9,767.00 |
| Dec 31, 2025 | 6,133.00 |
| Sep 30, 2025 | 4,006.00 |
| Jun 30, 2025 | 5,109.00 |
| Mar 31, 2025 | -1,758.00 |
| Dec 31, 2024 | 6,835.00 |
| Sep 30, 2024 | 3,721.00 |
| Jun 30, 2024 | -12,362.00 |
| Mar 31, 2024 | 19,813.00 |
| Dec 31, 2023 | 7,541.00 |
| Sep 30, 2023 | -3,656.00 |
| Jun 30, 2023 | 8,719.00 |
| Mar 31, 2023 | -148.00 |
| Dec 31, 2022 | -679.00 |
| Sep 30, 2022 | -4,038.00 |
| Jun 30, 2022 | -4,168.00 |
| Mar 31, 2022 | 3,467.00 |
| Dec 31, 2021 | 18,995.00 |
| Sep 30, 2021 | -205,993.00 |